Module 1: Beyond the Genome: The Functional Proteome, Metabolome & PTM Landscape in Oncology

1. Why Genomics Alone is Insufficient in Precision Oncology

Precision oncology historically prioritized next-generation sequencing (NGS) to discover somatic mutations, copy-number alterations, and gene fusions. However, genomic sequence represents potential rather than execution. Transcript abundance correlates weakly with protein concentration in human tissues ($R^2 \approx 0.30 - 0.45$), primarily due to variable ribosomal translation rates, alternative splicing, microRNA silencing, and targeted protein degradation via ubiquitin-proteasome pathways.

Proteins and metabolites constitute the direct functional effectors of malignant phenotypes:

• Post-Translational Modifications (PTMs): Oncogenic signaling cascades (EGFR, MAPK, PI3K/AKT/mTOR) are driven by dynamic phosphorylation, ubiquitination, and acetylation rather than changes in total protein abundance. A patient with wild-type EGFR may nonetheless exhibit aberrant hyperphosphorylation susceptible to tyrosine kinase inhibitors (TKIs).
• Metabolic Plasticity & Oncometabolites: Neoplastic transformation induces rapid rewiring of cellular metabolism (the classic Warburg effect of aerobic glycolysis, glutaminolysis, and altered lipid desaturation). Mutant metabolic enzymes synthesize neo-metabolites—such as $R(-)$-2-hydroxyglutarate ($2\text{-HG}$) in $IDH1/2$-mutant gliomas and AML—that directly inhibit $\alpha$-ketoglutarate-dependent dioxygenases, inducing genome-wide DNA hypermethylation.
• Intratumoral Spatial & Temporal Heterogeneity: Spatial proteomics and metabolomics reveal profound regional microenvironmental variations (hypoxia, acidosis, necrosis) across primary tumor core, invasive margins, and metastatic niches that genomic sequencing masks in bulk homogenates.

2. The Dynamic Range Barrier in Clinical Biofluids

The primary technical hurdle in clinical proteomics is dynamic range. In peripheral blood plasma, the 10 most abundant proteins (albumin, immunoglobulins, transferrin, haptoglobin) account for over $90\%$ of total protein mass, while clinically vital diagnostic biomarkers (cardiac troponins, cytokines, shed tumor antigens like PSA and CA-125) circulate in the low picogram-per-milliliter range ($\sim 10^{-12}\text{ g/mL}$):

$$\text{Dynamic Range} = \frac{[\text{Human Serum Albumin}]}{[\text{Interleukin-6}]} \approx \frac{45\text{ mg/mL}}{5\text{ pg/mL}} \approx 9 \times 10^9 \approx 10^{10}$$

Because mass spectrometers cannot amplify proteins analogously to PCR for nucleic acids, biomarker discovery demands either upfront high-abundance immuno-depletion columns, robust chromatographic fractionation, or sensitive targeted acquisition strategies.